reason report
bottom line gilead weaker top-lin miss due channel
inventori adjust vs consensu overshadow
strong underli hiv volum trend though lack guidanc
increas like leav stock recent rang
view strong launch trajectori new product biktarvi
descovey like prove durabl new market europ
new indic prep like boost growth product
one-tim tax windfal drove bottom-lin beat
investor like ignor ep consensu beat hiv product sale
miss consensu inventori headwind
larger street expect increasingli accustom
season howev hiv volum growth us
hiv infect truvada prep headwind
revers gilead hiv busi continu win
market share unlik disrupt near- mid-term
believ provid investor floor share price
largest debat gilead stock next month like
abil file filgotinib inhibitor complet rheumatoid
arthriti efficaci packag us without complet manta safeti
studi current timelin leav least anoth year
file put month behind key rival
mp quarter increas near-term
revenu estim reflect like strong recoveri report
hiv product sale new forecast consensu
also increas pro forma ep estim base
higher revenu control expens lower share count
quarter share repurchas base chang peer compani
multipl increas price target
reiter market perform rate
averag price-to-earnings large-cap revenu
multipl slower-growth medic co
sum part exist franchis
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm non-gaap ep ex stock option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate gilead stock market perform price target gilead matur
gener biotech compani search next wave innov growth
compani leader hiv medicin busi increas alreadi domin market
share indic expect hiv product sale grow peak
expect signific eros legaci tdf franchis gilead
also built lead posit hepat medicin busi continu show
sign steadi declin headi peak net two downgrad stock
sept chang hcv market forecast compani fallen
total revenu hcv sale declin stabil
compani experi moder revenu eros two franchis believ
worth compani recent share price rest compani pipelin
consist mainli kinas inhibitor filgotinib recent acquir program
yescarta time least question timelin valu
near term compani outlook much depend result pivot trial
nash medicin immedi selonsertib trial disappoint compani
stock price could suffer multipl compress expect compani revenu remain
rang next year earn hover rang
level stock seem like enjoy multipl line ex-growth matur
top line miss propel season weak hiv sale
gilead total revenu consensu estim
miss driven weaker hiv sale partial off-set stronger hcv sale
consensu predict usual sequenti declin quarter disclos
headwind larger anticip howev hcv sale benefit one-tim us
depart correct order wholesal inventori stock newli launch author
gener like anticip consensu
total hiv product sale consensu
estim miss driven aforement season inventori payer mix
headwind gilead disclos impact hiv product pro-rata basi
gilead latest launch hiv product biktarvi symtuza still beat consensu
biktarvi record sale sequenti gilead second largest hiv
product genvoya biktarvi start grow ex us market well new
countri open later trajectori remain strong genvoya hiv
medicin miss consensu singl digit percentag
total hcv sale consensu estim benefit
one-tim govern purchas undisclos amount gilead expect
purchas occur earlier anticip result gilead increas full-
year hcv revenu guidanc sale non-antivir product letairi ambisom zydelig
miss consensu like trend even neg view later
year effect gener competit ranexa letairi acceler yescarta sale
consensu expect
gross margin consensu forecast gross
margin increas non-gaap
consensu non-gaap sg consensu total gilead
expens consensu line estim gilead
oper margin line last year quarter effect tax rate
benefit one-tim tax settlement gilead still guid full-year tax rate
result tax windfal well reduc share count non-gaap dilut ep
consensu estim compani
oper cash flow quarter deploy dividend payment
share buyback debt retir compani net cash posit declin
total cash declin
guidanc reiter still consensu
gilead reiter aspect financi guidanc manag expect product
sale recent consensu estim gilead expect
product gross margin non-gaap
sg expens bracket consensu final
manag reiter expect effect tax rate line recent
consensu estim
gilead us hiv busi declin due inventori drawdown inventori
increas wholesal ahead predict earli price increas
govern fund aid drug assist program adap also increas purchas
accentu season effect payer channel receiv higher drug discount
pressur gross-to-net quarter
despit headwind us hiv volum growth remain strong gilead report us
patient gilead hiv product sequenti annual gilead report
growth hiv rx volum compar prior year growth led biktarvi
captur treatment-nav patient howev major biktarvi patient come
switch therapi genvoya competitor gsk
dolutegravir-bas regimen overal gilead report us treatment-nav patient
start gilead product us hiv patient current gilead product
gilead also benefit robust growth pre-exposur prophylaxi prep hiv market
truvada indic medicin today compani abl start
transit patient descovi year-end gilead estim peopl
take truvada prep end sequenti growth annual
clear updat filgotinib us regulatori file
gilead report success phase trial filgotinib rheumatoid arthriti
ra establish drug efficaci file drug europ second
half year howev stand file filgotinib still gate behind phase ii
manta safeti studi men ulcer coliti manta ray studi male ra
patient gilead provid inform progress recruit trial
gilead disclos recent submit meet request fda discuss
data trial whether file prior complet fda request
manta trial gilead expect meet mid-year updat investor
outcom whether filgotinib file without manta meet like
call
base result quarter manag commentari well high-level
analysi current trend hiv market increas revenu estim
forecast gilead total revenu increas
declin truvada atripla lose
exclus us increas total hiv revenu forecast margin
longer term biggest chang within hiv biktarvi increas
increas total hcv revenu forecast
decreas longer term revenu estim
consensu line
decreas forecast expens increas expens
forecast longer term ebit margin forecast percentag point higher
year approxim reduc expect share count
year account continu share repurchas result chang pro forma
ep estim increas longer term ep estim
consensu
base chang revenu forecast ep estim cash flow
increas price target gilead maintain market perform rate
price target inc base averag four approach
believ reason basi valu stock today approach trough
price earn multipl larg cap slow-growth medic product busi long term
revenu multipl larg cap medic product stock slow growth outlook sum
part valuat exist franchis discount cash flow dcf use trough consensu
forward earn multipl slow-growth medic product stock celg
appli ep estim gilead give price
altern appli slow-grow large-cap biopharma product
celg rhhbi nv revenu multipl revenu estim deriv
impli valu impli one year price target use sum part valuat
exist franchis get price consist primarili price
compani hiv franchis hcv product lastli dcf use forecast free
cash flow appli growth rate termin cash flow forecast
discount valu back present wacc give present valu
averag four approach price target
risk view outlook valuat gilead includ major chang label
price reimburs coverag compani exist hiv hcv product emerg
aggress price discount rebat valu eros hiv hcv
categori current forecast failur compani princip pipelin
asset selonsertib nash filgotinib ra ibd advanc develop
commerci opportun better perform valu expect includ
delay limit develop profil adopt competit hiv product
success develop underappreci element compani portfolio gs-
fxr agonist inhibitor follow-on car-t indic stronger-than-
expect convers current hiv patient gilead next gener taf-bas hiv treatment
royalti contract revenu
non-gaap cost good sold
share count period basic
guidanc
dilut ep impact relat acqusit
stock-bas compens
svb leerink llc research compani file zack factset consensu
svb leerink llc research compani file zack factset consensu
late stage pipelin program includ
late stage pipelin program exclud
million
symtuza darunavir/c/f-taf royalti
symtuza darunavir/c/f-taf royalti
svb leerink llc research compani file
million
sale incl emori amort
 total revenu
sg total revenu
profit share total revenu
svb leerink llc research compani file
brand
type event
event trial detail
date known
up/down
expect
svb leerink llc research compani file
phase result
phase result registr
phase ii result registr
phase result
file fda regulatori approv mcl
phase ii testicular safeti filgotinib result
manta gate nda
analysi stock price svb leerink target
method trough price earn multipl larg cap slow growth biopharma compani
trough larg cap valu healthcar stock multipl ep celg
impli valuat ep
number period
equiti
method revenu multipl slow growth outlook larg cap biopharma stock appli
svb leerink revenu estim gilead
comp ex growth larg cap revenu multipl
impli valu gilead revenu
share outstand gilead
impli year price base revenu
method part valuat exist franchis kite
method dcf base current late stage pipelin product declin flow
wacc growth termin period
present valu late stage market product flow termin valu
net debt
present valu late stage market product flow
averag method
svb leerink llc research compani file factset
